Nuclear Oncology Medical Care First in Illinois to Install and Perform AccuBoost, Non-Invasive Breast Cancer Treatment
Posted on: Wednesday, 8 August 2007, 15:09 CDT
WINFIELD, Ill., Aug. 8, 2007 (PRIME NEWSWIRE) -- Nuclear Oncology Medical Care, DuPage Oncology Center in Winfield became the first cancer center in Illinois to install the new AccuBoost System for image-guided treatment of breast cancer. Following the installation on August 8th the system was used to treat their first patient.
After selecting breast conserving treatment, 76-year old Mrs. G. Miller is the first in Illinois to undergo a site-specific radiation procedure, called AccuBoost. The treatment, performed in sessions over 8 days, is designed to deliver focused radiation to the lumpectomy cavity while minimizing the unintended exposure to the heart and lungs.
"This non-invasive, real time image-guided treatment ensures better targeting of the lumpectomy cavity and makes it possible to see what you treat and treat what you see," said DuPage Oncology Center Radiation Oncologist, Dr. Dennis Galinsky. Dr. Galinsky continued, "Mrs. Miller was an ideal candidate for this procedure due to the location and staging of her cancer."
Dr. Anantha Murthy, Associate Professor of Radiation Oncology at Rush Medical College and DuPage Oncology Center said, "When I saw this system at the recent American Brachytherapy Society meeting, I knew we needed to make it available to our patients. Targeting the boost dose has always been a challenge; this system solves the problem."
"Typically delivered prior to the main external beam breast irradiation, AccuBoost is presently used as a replacement for the electron boost that normally would follow the standard treatment," says DuPage Oncology Center's Chief of Medical Physics, Dr. Mohamed Hamadeh. "The breast is immobilized and imaged in a manner similar to mammography allowing a special applicator to be positioned, delivering the radiation with far better accuracy."
"We are pleased to announce the installation and first use of the AccuBoost procedure at DuPage Oncology Center. We chose DuPage Oncology Center as the first site in Illinois because of their reputation and expertise," stated Piran Sioshansi, Ph.D. President and CEO of Advanced Radiation Therapy.
Bruce Taylor, NREMT-P, Vice President, Marketing & Business Development said, "AccuBoost can be used either as the boost phase of Whole Breast Irradiation (WBI) or for 5-day Partial Breast Irradiation (PBI). It is the only system that allows non-invasive use of the High Dose Rate (HDR) source for treatment of breast cancer. Prior to AccuBoost, PBI was performed via an invasive technique of employing multiple protruding catheters or with inflatable balloon devices implanted into the breast."
Patients wanting additional information can find it at www.AccuBoost.com or may contact DuPage Oncology Center at 630-690-3400.
Video B roll from earlier treatment is Available. The treatment of this patient will continue until Tuesday August 14th. Video crews are welcome to attend a treatment. DuPage Oncology Center is located at 126 North Winfield Road, Winfield, IL 60190.
The AccuBoost(tm) logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3939
This news release was distributed by PrimeNewswire, www.primenewswire.com
CONTACT: Advanced Radiation Therapy Bruce Taylor, Vice President of Marketing & Business Development (508) 400-5876 bruce.taylor@AccuBoost.com
Source: PrimeNewswire
Related Articles
- SensiGen HPV Assay Enables Major Breakthrough in Diagnosis and Treatment of Head and Neck Cancer
- Cellerant Therapeutics Awarded $13.5 Million Contract for Treatment of Acute Radiation Syndrome From the Biomedical Advanced Research and Development Authority (BARDA)
- Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer After First-Line Chemotherapy
- Karolinska Hospital to Become First in Sweden to Offer Advanced RapidArc Cancer Treatments From Varian Medical Systems
- Amrubicin is Designated As an Orphan Medicinal Product By the European Commission for the Treatment of Small Cell Lung Cancer
- Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer
- New Data Shows Promising Antitumor Activity With Nab-Paclitaxel (ABRAXANE(R)) in Combination and As a Single Agent for the Treatment of Lung and Ovarian Cancers
- Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
- New Targets for Detection and Treatment of Small Cell Lung Cancer*
- Radiation Starves Cancer While Killing It
 |
 |
User Comments (0)
RSS Feeds